Thrombolytic therapy for cerebral infarction

Academic Emergency Medicine

Volumn 3, Issue 9, 1996, Pages 881-892

  Kothari, Rashmi ^a   Pancioli, Arthur ^a   Brott, Thomas ^a   Broderick, Joseph ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

cerebral infarction; streptokinase; stroke; thrombolytic therapy; tissue plasminogen activator

Indexed keywords

STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; EARLY DIAGNOSIS; EMERGENCY HEALTH SERVICE; HUMAN; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0029781604     PISSN: 10696563     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1553-2712.1996.tb03537.x     Document Type: Article

References (116)

1. Clarke RL, Clifton E. The treatment of cerebrovascular thromboses and embolism with fibrinolytic agents. Am J Cardiol. 1960; 6:546-51.
2. Herndon RM, Meyer JS, Johnson JF, Fibrinolysin therapy in thrombotic diseases of the nervous system. J Mich St Med Soc. 1960; 59:1684-92.
3. Meyer JS, Gilroy J, Barnhart MI, Johnson JF, Anticoagulants plus streptokinase therapy in progressive stroke. JAMA. 1964; 189:373.
4. Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Therapeutic thrombolysis in cerebral thromboembolism. Neurology. 1963; 13:927-37.
5. Fletcher AP, Alkjersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke. 1976; 7:135-42.
6. Fears R. Biochemical pharmacology and therapeutic aspects of thrombolytic agents. Pharmacol Rev. 1990; 42:202-22.
7. Larcan A, Laprevote-Heully MC, Lambert H, et al. Indications des thrombolytiques au cours des accidents vasculaires cerebraux thrombosants traites par ailleurs par O.H.B. (2ATA). Therapie. 1977; 32:259-70.
8. Sherry S. Thrombolytic therapy for noncoronary diseases. Ann Emerg Med. 1991; 20:396-404.
9. Levine MN. Bolus, front-loaded, and accelerated thrombolytic infusions for myocardial infarction and pulmonary embolism. Chest. 1991; 99 (suppl): 128S-134S.
10. Urokinase Pulmonary Embolism Trial Study Group. Urokinase-Streptokinase Embolism trial: A cooperative study. Phase 2 results. JAMA. 1974; 229: 1606-13.
11. Sharma GVRK, Burleson V, Sasahara A. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. New Engl J Med. 1980; 303:842-5.
12. Verstraete M, Bleifeld W, Brower RW, et al. Double-blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet. 1985; i:965-9.
13. Verstraete M, Bernard R, Bory M, et al. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous Streptokinase in acute myocardial infarction. Lancet. 1985; ii:842-7.
14. The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial, phase I findings. N Engl J Med. 1985; 312:932-6.
15. Yusuf S, Collins R, Peto R, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J. 1985; 6:556-85.
16. Khaja F, Walton J, Brymer J, et al. Intracoronary fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 1983; 308:1305-11.
17. Collen D, Topol E, Tiefenbrunn A, et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation. 1984; 70:1012-7.
18. Gruppo Italiano per Lo Studio Della Streptochinasi Nell' Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986; i:397-401.
19. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I; a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987; 76: 142-54.
20. Wilcox RG, Von Der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet. 1988: ii:525-30.
21. Zeumer H, Freitag HJ, Grzyska V, et al. Interventional neuroradiology: local intra-arterial fibrinolysis in acute vertebrobasilar thromboembolic disease. AJNR Am J Neuroradiol. 1983; 4: 401-4.
22. Henze T, Boerr A, Tebbe U, et al. Lysis of basilar artery occlusion with tissue plasminogen activator [letter]. Lancet. 1987; 2:1391.
23. Jafar JJ, Tan WS, Crowell RM. Tissue plasminogen activator thrombolysis of a middle cerebral artery embolus in a patient with an arteriovenous malformation. J Neurosurg. 1991; 74:808-12.
24. Kaufman HH, Lind TA, Clark DS. Non-penetrating trauma to the carotid artery with secondary thrombosis and embo-lism: treatment by thrombolysin. Acta Neurochir. 1977; 37:219-44.
25. Nenci GG, Gresele P, Taramelli M, Agnelli G, Signorini E. Thrombolytic therapy for thromboembolism of vertebrobasilar artery. Angiology. 1983; 34:361-71.
26. Zeumer H, Hacke W, Kolmann HL, Poeck K. Lokale fibrinolysetherapie bei basilaris-thrombose. Dtsch Med Wochenschr. 1982; 107:728-31.
27. Zeumer H, Ferbert A, Ringelstein EB. Local intra-arterial fibrinolytic therapy in inaccessible internal carotid occlusion. Neuroradiology. 1984; 26:315-7.
28. Jungreis CA, Wechsler LR, Horten JA. Intracranial thrombolysis via a catheter embedded in the clot. Stroke. 1989; 20: 1578-80.
29. Haley EC Jr, Levy DE, Brott TG, et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke. 1992; 23:641-5.
30. Brott TG, Haley EC Jr, Levy DE, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992; 23:632-40.
31. Von Kummer R, Forsting M, Hacke W, Sartor K. Recanalization, infarct volume, cerebral hemorrhage, and clinical outcome after intravenous recombinant tissue plasminogen activator and heparin in acute carotid territory stroke. In: del Zoppo GJ, Mori E, Hacke W (eds). Thrombolytic Therapy in Acute Ischemic Stroke II. Berlin-Heidelberg: Springer-Verlag, 1993, pp 53-8.
32. Neuhaus KL, Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis Therapy (HITT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation. 1994; 90:1638-42.
33. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992; 32:78-86.
34. Roncagliona C. Multicenter Acute Stroke Trial-Italy (MAST-I) poster presentation at 20th International Joint Conference on Stroke and Cerebral Circulation. February, 1995. Stroke. 1995; 26:163.
35. Donnan GA, Davis SM, Chambers BR, et al. Australian Streptokinase Trial (ASK). In: del Zoppo GJ, Mori E, Hacke W (eds). Thrombolytic Therapy in Acute Ischemic Stroke II. Berlin-Heidelberg: Springer-Verlag, 1993, pp 80-5.
36. Fisher M, Pessin M, Furian A. ECASS: lessons for future thrombolytic stroke trials. JAMA. 1995; 274:1058-9.
37. Hacke W, Kaste M, Fiescui C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study. JAMA. 1995; 274:1-17.
38. Ringelstein EB, Biniek R, Weiller C, Ammeling B, Nolte PN, Thron A. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology. 1992; 42:289-98.
39. von Kummer R, Holle R. Rosin L, Forsting M, Hacke W. Does arterial recanalization improve outcome in carotid territory stroke? Stroke. 1995; 26:581-7.
40. Symon L, Branston NM, Strong AJ, Hope TD. The concept of thresholds of ischemia in relation to brain structure and function. J Clin Pathol. 1977; 30(suppl II): 149-54.
41. Jones TH, Morawetz RB, Crowell RM, et al. Threshold of focal ischemia in awake monkeys. J Neurosurg. 1981; 54: 773-82.
42. Crowell RM, Olsson Y, Klatzo I, Ommaya A. Temporary occlusion of the middle cerebral artery in the monkey: clinical and pathological observations. Stroke. 1970; 1:439-48.
43. Sundt TM Jr, Grant WC, Garcia JH. Restoration of middle cerebral artery flow in experimental infarction. J Neurosurg. 1969; 80:336-9.
44. Centeno RS, Hackney DB, Rothrock JR. Streptokinase clot lysis in acute occlusions of the cranial circulation: study in rabbits. AJNR Am J Neuroradiol. 1985; 6:589-94.
45. Zivin JA, Lyden PD, DeGirolami U, et al. Tissue plasminogen activator reduction of neurologic damage after experimental embolic stroke. Arch Neurol. 1988; 45:387-91.
46. DeLey G, Weyne J, Demeester G, et al. Experimental thromboembolic stroke studied by positron emission tomography: immediate versus delayed reperfusion by fibrinolysis. J Cereb Blood Flow Metab. 1988; 8:539-45.
47. Clark WM, Madden KP, Zivin JA, Lyden PD, Sasse KC. Intracerebral hemorrhage: tPA versus Streptokinase thrombolytic therapy [abstract]. Neurology. 1989; 39(Suppl 1):183.
48. Hirschberg M, Hofferberth B. Thrombolytic therapy with urokinase and prourokinase in a canine model of acute stroke. Neurology. 1987; 37(suppl 1): 132.
49. Hirschberg M, Korves M, Koc I, Hofferberth B, Wiesmann W. Untersuchungen zur Thrombolyse zerebraler thrombembolien mittels urokinase an einem tiermodell. Schweiz Med Wochenschr. 1987; 117:1811-3.
50. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science. 1985; 330:1289-92.
51. del Zoppo GJ, Copeland BR, Waltz TA, Zyroff J, Plow EF, Harker LA. The beneficial effect of intracarotid urokinase on acute stroke in a baboon model. Stroke. 1986; 17:638-43.
52. Slivka A, Pulsinelli W. Hemorrhagic complications of thrombolytic therapy in experimental stroke. Stroke. 1987; 18:1148-56.
53. Dujovny M, Vasquez M, Diaz FG, Ausman JI, Mirchandani HG, Berman SK. Anatomical basis for lenticulostriate microvascular surgery. Stroke. 1987; 18: 292.
54. Alberts MJ, for the rt-PA Acute Stroke Study Group. A safety and efficacy study of intravenous rt-PA in patients with acute stroke. In: del Zoppo GJ, Mon E, Hacke W (eds). Thrombolytic Therapy in Acute Ischemic Stroke II. Berlin-Heidelberg: Springer-Verlag, 1993, pp 45-52.
55. Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ, rt-PA Acute Stroke Study Group. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. AJNR Am J Neuroradiol. 1993; 14:3-13.
56. Fieschi C, Argentino C, Lenzi GL, Sacchetti ML, Toni D, Bozzao L. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci. 1989; 92:311-22.
57. Yamaguchi T, Hayakawa T, Kikuchi H, for the Japanese Thrombolysis Study Group. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis. 1993; 3:269-72.
58. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology. 1992; 42:976-82.
59. Huemer M, Niederwieser V, Ladurner G. Thrombolytic treatment for acute occlusion of the basilar artery. J Neurol Neurosurg Psychiatry. 1995; 58:227-8.
60. Jorgensen HS, Sperling B, Nakayama H, Raaschou HO, Olsen TS. Spontaneous reperfusion of cerebral infarcts in patients with acute stroke. Arch Neurol. 1994; 51:865-73.
61. Irino T, Taneda M, Minami T. Angiographic manifestations in postrecanalized cerebral infarction. Neurology. 1977; 27:471-5.
62. Barsan WG, Brott TG, Olinger CP, Marier JR. Early treatment for acute ischemic stroke. Ann Intern Med. 1989; 111:449-51.
63. Bratina P, Greenberg L, Pasteur W, Grotta JC. Current emergency department management of stroke in Houston, Texas. Stroke 1995; 26:409-14.
64. Tilley BC, for the NINDS tPA Stroke Trial Investigators. A Deming approach to recruiting: The National Institute of Neurological Diseases and Stroke (NINDS) tPA Stroke Trial experience. In: del Zoppo GJ, Mori E, Hacke W (eds). Thrombolytic Therapy in Acute Ischemic Stroke II. Berlin-Heidelberg: Springer-Verlag, 1993, pp 282-4.
65. Alberts M, Brass L, Perry A, Webb D, Dawson D. Evaluation times for patients with in-hospital strokes. Strokes. 1993; 24:1817-22.
66. Ho MT, Eisenberg MS, Litwin PE, Schaeffer SM, Damon SK. Delay between onset of chest pain and seeking medical care: the effect of public education. Ann Emerg Med. 1989; 7:11-5.
67. Kothari R, Hall K, Broderick T, Brott T. Early stroke recognition: a prehospital stroke scale [abstract]. Ann Emerg Med. 1996; 27:130.
68. Kothari R, Barsan W, Brott T, Broderick J, Ashbrock S. Frequency and accuracy of prehospital diagnosis of acute stroke. Stroke. 1995; 26:937-41.
69. Kothari RU, Brott TG, Broderick JP, Gorgas DL. Emergency department thrombolytic therapy for stroke: assessing patient eligibility [abstract]. Acad Emerg Med. 1994; 1:A47.
70. Hacke W, Kaste M, Fieschi C, for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA. 1995; 274:1017-25.
71. Lyden PD, Lau GT. A critical appraisal of stroke evaluation and rating scales. Stroke. 1991; 22:1345-52.
72. del Zoppo GJ. Acute stroke - on the threshold of a therapy? [editorial]. N Engl J Med. 1995; 333:1632-3.
73. Hommel M, Boissel JP, Comu C, et al. for the MAST Study Group. Termination of trial of streptokinase in severe acute ischaemic stroke [letter]. Lancet. 1994; 315:57.
74. The MAST-I Collaborative Group. Thrombolytic and antithrombotic therapy in acute ischemic stroke. Multicenter Acute Stroke Trial-Italy (MAST-I) Group. In: del Zoppo GJ, Mori E, Hacke W (eds). Thrombolytic Therapy in Acute Ischemic Stroke II. Berlin-Heidelberg: Springer-Verlag, 1993, pp 86-94.
75. Multicentre Acute Strok Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet. 1995; 346:1509-14.
76. Shahar E, McGovern P. Trials of streptokinase in severe acute ischaemic stroke. Lancet. 1995; 345:578-9.
77. Haley EC Jr, Brott TG, Sheppard GL, et al., for the tPA Bridging Study Group. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke. 1993; 24:1000-4.
78. The NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333:1581-7.
79. Davies SW, Ranjadayalan K, Wickens DG, Dormandy TL, Timmis AD. Lipid peroxidation associated with successful thrombolysis. Lancet. 1990; 335:741-3.
80. Koudstaal PJ, Stibbe J, Vermeulen M. Fatal ischaemic brain oedema after early thrombolysis with tissue plasminogen activator in acute stroke. Br Med J. 1988; 297:1571-4.
81. Marder VJ, Hirsh J, Bell WR. Rationale and practical basis of thrombolytic therapy. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds). Haemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd edition. Philadelphia: J. B. Lippincott, 1994, pp 1514-41.
82. Zeumer H, Freitag HJ, Zanella F, Thie A, Arning C. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (rt-PA). Neuroradiology. 1993; 35:159-62.
83. Ezura M, Kagawa S. Selective and superselective infusion of urokinase for embolie stroke. Surg Neurol. 1992; 38: 353-8.
84. Wong MC, Htoo A. A pilot study of early angiography and intra-arterial streptokinase for acute ischemic stroke [abstract]. Neurology. 1993; 43:A263.
85. Hacke W, Zeumer H, Ferbert A, Bruckmann H, del Zoppo GJ. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke. 1988; 19: 1216-22.
86. Casto L, Moschini L, Camerlingo M, et al. Local intra-arterial thrombolysis for acute stroke in the carotid artery territories. Acta Neurol Scand. 1992; 86: 308-11.
87. Fletcher AP, Alkjaersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke. 1976; 7:135-42.
88. Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke. 1988; 19: 802-12.
89. Hiramoto M, Yoshimizu N, Satoh K, Takamatsu S. Intra-arterial urokinase therapy in thromboembolic stroke [abstract]. Stroke. 1994; 25:268.
90. Sasaki O, Takeuchi S, Koike T, Koizumi T, Tanaka R. Fibrinolytic therapy for acute embolic stroke: intravenous, intracarotid, and intra-arterial local approaches. Neurosurgery. 1995; 36:246-53.
91. LaMonte MP, Hurst RW, Raps EC, et al. Selective intra-arterial thrombolysis for acute cerebral ischemia: a case - control comparison. Neurology. 1995; 45 (suppl 4):A469.
92. Barnwell SL, Clark WM, Nguyen TT, O'Neill OR, Wynn ML, Coull BM. Safety and efficacy of delayed intra-arterial urokinase therapy with mechanical clot disruption for thromboembolic stroke. AJNR Am J Neuroradiol. 1994; 15:1817-22.
93. Higashida RT, Halbach VV, Barnwell SL, Dowd CF, Hieshima GB. Thrombolytic therapy for acute stroke. J Endovasc Surg. 1994; 1:4-15.
94. Torr SR, Nachowiak DA, Fujii S, Sobel BE. "Plasminogen steal" and clot lysis. J Am Coll Cardiol. 1992; 19:1085-90.
95. Dehmer GJ, Gresalfi N, Daly D, Oberhardt B, Tate D. Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents. J Am Coll Cardiol. 1995; 25:1069-75.
96. Granger CB, Gabriel DA, Reese NS, et al. Fibrin modification by ionic and nonionic contrast media during cardiac catheterization. Am J Cardiol. 1992; 69: 821-2.
97. Courtheoux P, Theron J, Derlon JM, Alachkar F, Casasco A. In situ fibrinolysis in supra-aortic main vessels. A preliminary study. J Neuroradiology. 1986; 13:111-24.
98. Tsai FY, Berberian B, Matovich V, Lavin M, Alfieri K. Percutaneous transluminal angioplasty adjunct to thrombolysis for acute middle cerebral artery rethrombosis. AJNR Am J Neuroradiol. 1994; 15:1823-9.
99. Troughton AH, Morgan RA, Paxton RM, Wells IP. External carotid angioplasty in the treatment of developing stroke. Br J Radiol. 1992; 65:825-7.
100. Morgan MK, Grinnell V, Little N, Day MJ Jr. Successful treatment of an acute thrombosis of an intracranial vertebral artery endarterectomy with urokinase. Neurosurgery. 1994; 35:978-81.
101. Barr J, Horowitz M, Mathis J, Sclabassi R, Yonas H. Intraoperative urokinase infusion for embolie stroke during carotid endarterectomy. Neurosurgery. 1995; 36:606-11.
102. Mayer TE, Bruckmann H, Mull M, Thron A. High dose local intra-arterial fibrinolytic therapy improves the outcome in acute vertebrobasilar occlusion. In: Chicago: Proceedings of the 33rd Annual Meeting of the American Society of Neuroradiology, 1995, p 69.
103. Bernik MB, Kwaan HC. Plasminogen activator activity in cultures from human tissues. An immunological and histochemical study. J Clin Invest. 1969; 48:1740-53.
104. White WF, Barlow GH, Mozen MM. The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry. 1966; 5:2160-9.
105. Loscalzo J, Braunwald E. Tissue plasminogen activator. N Engl J Med. 1988; 319:925-31.
106. Hirsh J, Salzman EW, Marder VJ, Colman RW. Overview of the thrombolytic process and its therapy. In: Colman RW, Hirsh J, Marder VJ. Salzman EW (eds). Hemostasis and thrombosis: Basic Principles and Clinical Practice, 3rd edition. Philadelphia: J. B. Lippincott, 1994; pp 1151-63.
107. Paoni NF, Keyt BA, Refino CJ, et al. A slow clearing, fibrin-specific, PAI-I resistant variant of tPA (T103N, KHRR 296-299 AAAA). Thromb Haemost. 1993; 70:307-12.
108. Vermeer F, Bar F, Windeler J, Schenkel W. Saruplase, a new fibrin specific thrombolytic agent: final results of the PASS study (1698 patients) [abstract]. Circulation. 1993; 88:1292.
109. Martin U, Sponer G, Strein K. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. J Am Coll Cardiol. 1992; 19:433-40.
110. Olinger CP, Brott TG, Barsan WG, et al. Use of Ancrod in acute or progressing ischemic cerebral infarction. Ann Emerg Med. 1988; 17:1208-9.
111. Witt W, Maass B, Baldus B, Hildebrand M, Donner P, Schleuning WD. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Circulation. 1994; 90:421-6.
112. Wade DT, Hewer RL. Functional abilities after stroke: measurement, natural history and prognosis. J Neurol Neurosurg Psychiatry. 1987; 50:177-82.
113. Dombovy ML, Basford JR, Whisnant JP, Bergstralh EJ. Disability and use of rehabilitation services following stroke in Rochester, Minnesota. 1975-1979. Stroke. 1987; 18:830-6.
114. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988; 19:604-7.
115. Teasdale G, Knill-Jones R, Van der Sand J. Observer variability in assessing impaired consciousness and coma. J Neurol Neurosurg Psychiatry. 1978; 41: 603-10.
116. Brott T, Adams H, Olinger C, et al. Measurement of acute cerebral infarction: clinical examination scale. Stroke. 1989; 20:864-70.